Department of Neurological Surgery, Cooper Neurological Institute, Cooper University Health Care, Camden, New Jersey, USA.
Cooper Medical School of Rowan University, Camden, New Jersey, USA.
Oper Neurosurg (Hagerstown). 2023 May 1;24(5):469-475. doi: 10.1227/ons.0000000000000656. Epub 2023 Mar 10.
Middle meningeal artery embolization (MMAE) for chronic subdural hematomas (cSDHs) has evolved as a potential treatment alternative for these lesions. The indications for using this treatment modality and the pathophysiology of cSDHs are an area of considerable interest. A retrospective review was performed including all major papers addressing this topic. Although considered a relatively new treatment option, MMAE for cSDHs is gaining widespread popularity. There are many questions that need to be addressed regarding its indications, some of which are the subject of ongoing clinical trials. The efficacy of this treatment modality in carefully selected patients has also provided new insights into the potential pathophysiology of cSDHs. This concise review will focus on the current evidence supporting the use of embolization in the treatment of this disease and highlight unanswered relevant clinical questions regarding MMAE indications and technique.
脑膜中动脉栓塞术（MMAE）治疗慢性硬脑膜下血肿（cSDH）已成为此类病变的一种潜在治疗选择。使用这种治疗方式的适应证和 cSDH 的病理生理学是一个非常关注的领域。进行了一项回顾性研究，包括所有涉及该主题的主要论文。尽管被认为是一种相对较新的治疗选择，但 MMAE 治疗 cSDH 正在广泛普及。关于其适应证存在许多需要解决的问题，其中一些问题是正在进行的临床试验的主题。这种治疗方式在精心挑选的患者中的疗效也为 cSDH 的潜在病理生理学提供了新的见解。本简明综述将重点介绍支持栓塞治疗该疾病的当前证据，并突出有关 MMAE 适应证和技术的未解答的相关临床问题。
